Encouraging Preliminary Clinical Results Reported for Immune-based Therapy Remune(TM) [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

Encouraging Preliminary Clinical Results Reported for Immune-Based Therapy Rm-INE,'
Page 2
July 2, 1998
significant improvement in several markers of immunologic response such as lymphocyte proliferation
to HIV antigens and responses to native p24, gpl20-depleted HIV, and whole BaL 111iV. No
significant difference in more general immune responses to candida,,trcpt okin,;e Uf Cthnu<' H,,
was observed between groups. Additionally, patients receiving HAART + the IRiC llIVuVi'iui.~uw,
experienced significant increases in production of MIP-1I beta (a beta-chemokine associated with viral
suppression) compared to the HAART + placebo group.
"This HIV-specific lymphocyte proliferative immune response in patients receiving the IRC HIV
immunogen + HAART," commented Dr. Valentine, "is comparable to that seen in some individuals
with nonprogressive disease."
This 32 week study was designed and initiated at the New York University Medical Center in New
York; the North Shore University Hospital in Manhasset, New York, the Johns Hopkins University
School of Medicine in Baltimore, the Chicago Medical School, the Center for Blood Research in
Boston, the University of California at Irvine, the University of California at Davis, and the Institute for
Human Virology in Baltimore also participated.
New York University Medical Center is one the nation's leading biomedical resources, combining
excellence in patient care, research and medical education.